About MEAJO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions to authors | Online submission | Subscribe | Advertise | Contact | Login 
Middle East African Journal of Ophthalmology Middle East African Journal of Ophthalmology
Users Online: 1235   Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
REVIEW ARTICLE
Year : 2012  |  Volume : 19  |  Issue : 1  |  Page : 83-87

The use of antivascular endothelial growth factor agents in the perioperative period in diabetic vitrectomy


1 Department of Special Surgery, Division of Ophthalmology, The University of Jordan, Amman, Jordan
2 Department of Ophthalmology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA

Correspondence Address:
Sophie J Bakri
Department of Ophthalmology, Mayo Clinic, 200 First Street, S.W. Rochester, MN 55905
USA
Login to access the Email id

Source of Support: Research to Prevent Blindess, New York, NY, Conflict of Interest: None


DOI: 10.4103/0974-9233.92120

Rights and Permissions

Pars plana vitrectomy is an established surgical method for the treatment of proliferative diabetic retinopathy and its complications. Anti-vascular endothelial growth factor agents suppress vascular proliferation and may be used as pharmacological adjuvants to reduce the incidence of postoperative hemorrhage in the vitreous cavity and to facilitate the surgical approach. We conducted an electronic search to identify prospective randomized controlled trials looking at the use of -perioperative vascular endothelial growth factor suppression in diabetic patients undergoing vitrectomy. We found six prospective randomized trials with only one being double-masked. We present a summary of the findings. Four studies suggest that the use of perioperative, anti-vascular endothelial growth factor agents facilitate vitrectomy surgery, but only one study supports their use to reduce the chances of early postoperative vitreous bleeding. Two studies did not find a significant benefit for their use before surgery to reduce the recurrence of vitreous hemorrhage in proliferative diabetic retinopathy. More randomized double blinded studies with a larger number of patients are needed to establish a clear recommendation regarding the use of these agents. Those studies should factor in the use of endo-tamponade with gas or silicone oil following vitrectomy.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3295    
    Printed280    
    Emailed0    
    PDF Downloaded158    
    Comments [Add]    

Recommend this journal